CD14 (CD14 Molecule)

News alerts, weekly reports and conference planners

Entrez ID:

CD14 expression	Acute Myelogenous Leukemia	CD14 expression	Acute Myelogenous Leukemia	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3
CD14 overexpression	Hodgkin Lymphoma	CD14 overexpression	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3
CD14 overexpression	Acute Myelogenous Leukemia	CD14 overexpression	Acute Myelogenous Leukemia	venetoclax + palbociclib Sensitive: C3 – Early Trials venetoclax + palbociclib Sensitive : C3	venetoclax + palbociclib Sensitive: C3 – Early Trials venetoclax + palbociclib Sensitive : C3
PD-L1 expression + CD14 positive	Clear Cell Renal Cell Carcinoma	PD-L1 expression + CD14 positive	Clear Cell Renal Cell Carcinoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3

Associations(4)